The CheckMate 901 trial compared Opdivo-Yervoy with gemcitabine-carboplatin for cisplatin-ineligible metastatic urothelial carcinoma patients. Despite negative trial results, the FDA approved Opdivo ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

In a real-world study, only 35% of patients completed the full guideline-recommended 4-6 cycles of chemotherapy as first-line treatment for metastatic bladder cancer. Real-world data show suboptimal ...

Pharmaceutical treatment for urinary tract infections (UTI) is significantly associated with a higher risk for a delayed diagnosis of muscle-invasive or metastatic bladder cancer. Treatment for ...

By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

Cancer’s cruelest trick is its ability to disappear, only to reappear years later in a new organ or a familiar scar. The fear ...

Urothelial carcinoma is cancer of the urinary system. The urothelium is a kind of epithelial (protective) lining of the urinary system, which includes the urinary tract, bladder, your ureters (the ...

Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...

A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...